Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced submission of an Investigational New Drug (IND) application to the Department of Health, Abu Dhabi (DOH) for PRECISION-E2, a first-of-its-kind, Phase 2a genomics-enabled clinical trial evaluating Teverelix® in women with symptomatic endometriosis in the United Arab Emirates (UAE).

The PRECISION-E2 study is designed to combine clinical outcomes, hormonal biomarkers, pharmacokinetic and pharmacodynamic measurements, and genomic analyses to better understand treatment response variability in women suffering from endometriosis. The study will leverage participants enrolled in the Emirati Genome Program (EGP), one of the world's largest national genomics initiatives, creating a unique opportunity to explore how genetic variation may influence response to hormonal therapy.